Thesis
ArchiMed closes $1.1B take-private of bempedoic acid franchise; CVR holders bet on 2027-2030 net sales milestones
Esperion was acquired by ArchiMed on July 13, 2026 for $3.16 per share cash plus CVRs worth up to $100 million tied to bempedoic acid and bumetanide net sales through 2030. The residual investable question is whether those sales milestones are achieved, contingent on commercial uptake sustaining after delisting and private operation. The CVR structure carries no recourse if milestones are missed, and the company no longer operates as a public equity.
Focus
CVR milestone payments (up to $100M aggregate)
TBD
Bull
If NEXLETOL (bempedoic acid) sustains its commercial momentum — building on 21% revenue growth, 90%+ payer coverage, Class I/Level A ESC/EAS guideline inclusion, 700K+ patients treated in Europe, and expanding provider adoption — net sales across the 2027-2030 milestone periods hit the specified thresholds, and CVR holders receive the full $100 million in aggregate contingent payments, validating ArchiMed's thesis that the franchise was undervalued as a public company.
Bear
The most likely failure modes are a slower-than-projected U.S. revenue ramp driven by persistent prior authorization friction or formulary positioning pressures from entrenched PCSK9 inhibitors, generic erosion if patent settlements are challenged, or underperformance of Enbumyst in the CHF edema market, any of which could cause net sales to fall below one or more milestone thresholds and result in partial or zero CVR payouts.
Unlock the full thesis for ESPR.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.